The new antiepileptic drug (AED) lacosamide (vimpat, "UCB Pharma") with a new mechanism of action was registered in Russia in 2010. The drug should be used as add-on treatment in patients over 16 years and older with non-controlled focal seizures with- or without secondary localization. The authors review the data of literature and the results of trials on efficacy and safety of lacosamide for peroral and intravenous introduction. Randomized clinical trials of the peroral form of this drug provide evidence that lacosamide is a prospective preparation for complex treatment of drug-resistant epilepsy in the view of its safety and tolerability. The availability of the infusion form is advantageous compared to other AED making it possible to continue treatment in cases when the peroral intake of AED is temporary impossible.